Quick Answer
Citius Pharmaceuticals, Inc. reported Net Income Loss of -$32.54 million for the year ending 2023.
- Citius Pharmaceuticals, Inc. showed an increase of +3.3% in Net Income Loss from 2022 to 2023.
- This data is from Citius Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on December 29, 2023.
- XBRL data for this metric is available from 2010 to 2023 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2023), Citius Pharmaceuticals, Inc.'s Net Income Loss has declined by 209,854.3%.
- Historical annual values: Fiscal year 2023: -$32.54 million | Fiscal year 2022: -$33.64 million | Fiscal year 2021: -$23.05 million | Fiscal year 2020: -$17.55 million | Fiscal year 2019: -$15.56 million | Fiscal year 2018: -$12.54 million | Fiscal year 2017: -$10.38 million | Fiscal year 2016: -$8.30 million | Fiscal year 2015: -$2.90 million | Fiscal year 2014: -$737.7 thousand | Fiscal year 2013: -$1.29 million | Fiscal year 2013: -$31.4 thousand | Fiscal year 2012: -$22.0 thousand | Fiscal year 2011: -$26.3 thousand | Fiscal year 2010: -$15.5 thousand | Fiscal year 2010: -$15.5 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: